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PTHrPProstate cancer frequently metastasizes to the skeleton but the underlying mechanism remains largely unde-
ﬁned. Discoidin domain receptor 2 (DDR2) is a member of receptor tyrosine kinase (RTK) family and is activated
by collagen binding. This study aimed to investigate the function and detailed mechanism of DDR2 in prostate
cancer bone dissemination. Herein we found that DDR2 was strongly expressed in bone-metastatic prostate
cancer cells and tissues compared to that in normal controls. Enhanced expression of constitutively activated
DDR2 led to elevation inmotility and invasiveness of prostate cancer cells, whereas knockdown of DDR2 through
speciﬁc shRNA caused a dramatic repression. Knockdown of DDR2 in prostate cancer cells resulted in signiﬁcant
decrease in the proliferation, differentiation and function of osteoblast. Over-expression of DDR2 in prostate can-
cer cells resulted in notable acceleration of osteoclast differentiation and bone resorption,whereas knockdownof
DDR2 exhibited the opposite effects. An intrabone injection bone metastasis animal model demonstrated that
DDR2 promoted osteolyticmetastasis in vivo. Molecular evidence demonstrated that DDR2 regulated the expres-
sion, secretion, and promoter activity of parathyroid hormone-related protein (PTHrP), viamodulating Runx2
phosphorylation and transactivity. DDR2 was responsive to TGF-β and involved in TGF-β-mediated osteoclast
activation and bone resorption. In addition, DDR2 facilitated prostate cancer cells adhere to type I collagen.
This study reveals for the ﬁrst time that DDR2 plays an essential role in prostate cancer bone metastasis. The
mechanism disclosure may provide therapeutic targets for the treatment of prostate cancer.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer (PCa) is the second most frequently diagnosed
cancer and the second leading cause of cancer death in men after lung
cancer [1,2]. The incidence andmortality rate of prostate cancer are sig-
niﬁcantly higher in developed countries especially the United States,
where 186,000 new cases are diagnosed and 28,600 deaths occurred
due to it in 2008 [3]. In the United Kingdom, the statistic data was
about 35,000 cases and 10,000 deaths annually [4]. The skeleton is the
most frequent metastatic site for aggressive prostate cancer, with a fre-
quency of nearly 80%. Prostate cancer bonemetastases cause intractable
pain, spinal cord compression, pathologic fracture, hypercalcemia, and
lead to poor quality of life as well as reduced life expectancy [5].
The progression of prostate cancer metastasizing to the bones is
a complex process involving bone-tumor cell crosstalk mediated byin domain receptor 2; PTHrP,
lloproteinase
'an Shaanxi 710061, PR China.various cytokines and factors [6,7]. In the bone metastatic site, PCa
cells secrete factors to stimulate matrix resorption and bone destruc-
tion, and cytokines (such as TGF-β) are released to facilitate PCa cells
with active proliferation and dissemination capacities [8,9]. On the
other hand, PCa cells produce multiple osteolytic mediators to cause
further bone resorption and the so-called vicious cycle [10], among
which parathyroid hormone-related protein (PTHrP) is probably the
most important one, since approximately 90% of prostate cancer pa-
tients with bone metastases have elevated levels of PTHrP. Tumor cell
derived PTHrP binds to its receptor PTHR1 on osteoblast and stimulates
the osteoblast express receptor activator of nuclear factor κB ligand
(RANKL), which is responsible for the induction of osteoclast differenti-
ation and activation [11–15].
Bone metastatic prostate cancer cells highly express bone-related
genes that contribute to osteomimetic characteristics [16]. Runt-related
transcription factor 2 (Runx2, also known as Osf2/Cbfa1, AML3, or
Pebp2αA), a crucial transcription factor in osteogenic commitment, is
one of the most signiﬁcant osteomimetic genes [17,18]. Runx2 plays
important roles in prostate cancer bonemetastasis via regulating the ex-
pression of RANKL, osteopontin (OPN), bone sialoprotein (BSP), vascular
1351Z. Yan et al. / Biochimica et Biophysica Acta 1842 (2014) 1350–1363endothelial growth factor (VEGF), and matrix metalloproteinase 2, 9, 13
(MMP2, 9, 13) to participate in bone turnover [19,20]. Runx2 responds to
TGF-β stimulation by up-regulating the expression of Indian hedgehog
(IHH), which in turn increases the level of PTHrP [21]. Blockade of
the Runx2-IHH axis in breast cancer cells by targeting Runx2 with
short hairpin RNA prevents osteolytic disease [22].
Discoidin domain receptor 2 (DDR2) belongs to the receptor tyro-
sine kinase (RTK) family and is activated by collagen binding [23,24].
A unique feature that distinguishes DDR2 from other RTKs is that its
activation by collagen is very slow and sustained (by hours), compared
to the rapid response of typical RTKs to their ligands (by seconds to
minutes) [24]. The main functions of DDR2 are to 1) control the remod-
eling of ECMby regulating the expression and activity ofMMPs [25–27],
2) promote cell proliferation, adhesion and migration [28–32],
3) stimulate osteoblast differentiation and bone formation by regu-
lation of the transcription activity and phosphorylation of Runx2 in
an ERK MAPK-dependent manner [33,34]. In tumor, DDR2 partici-
pates in the process of melanoma liver metastasis [35], colorectal
cancer metastasis [36], as well as the progression of nasopharyngeal
carcinoma (NPC) [37], aneuploid papillary thyroid carcinomas [38],
and breast carcinoma [39–41]. Furthermore, DDR2 is up-regulated
by TGF-β and is involved in TGF-β-induced EMT in A549 lung cancer
cells [42].
In the present study, we demonstrate that DDR2 is highly expressed
in bonemetastatic PCa cells and tissues, and is associatedwith increased
motility and invasiveness of PCa cells. DDR2 promoted activation ofFig. 1.DDR2 is highly expressed in bonemetastatic PCa cells and tissues. (A)mRNA analysis of D
for total RNA isolation. RT-PCR was carried out with the indicated primers. (B) Immunoblo
immunoblottedwith the anti-DDR2 antibody, andβ-actinwas used for the loading control. Resu
to the RWPE-1 cells (right panel). *p b 0.05 vs RWPE-1 group. (C) Immunostaining for DDR2 in Hosteoblast and osteoclast in vitro and boosted the formation of osteolytic
lesions in vivo.We also elucidated the underlyingmechanism thatDDR2
regulates PTHrP viamodulating the phosphorylation and transactivity
of Runx2. In addition, DDR2 was involved in TGF-β-mediated bone
resorption, and facilitated the adhesion of PCa cells to type I collagen.
Our study aims to provide a novel potential target for PCa treatment
in future.
2. Results
2.1. DDR2 is highly expressed in bone metastatic PCa cells and tissues
To investigate whether DDR2 participates in prostate cancer pro-
gression especially in bone metastasis, we examined the expression
levels of DDR2 in normal prostate epithelial RWPE-1 and several
PCa cells, including, brain metastatic DU145, lymph-node metastatic
LNCaP, and bone metastatic MDA PCa 2b, VCaP, and PC-3. As shown in
Fig. 1A, elevated mRNA levels of DDR2 were observed in PCa cells com-
pared to normal prostate cells, and the mRNA level of DDR2 in bone
metastatic cells wasmuch higher than in the lymph-node or brain met-
astatic cells. Fig. 1B demonstrates that the protein levels of these cell
lines were consistentwith the RNA levels obtained from RT-PCR results.
The protein level of DDR2 in PC-3 cells was approximately 3-fold com-
pared to that of LNCaP cells. Furthermore, immunohistochemistry anal-
ysis in tissue samples revealed that DDR2 expression was detectable in
10.53% of benign prostatic hyperplasia (BPH) and high grade prostaticDR2 in different cell lines. Cellswere cultured in the indicatedmediumandwere harvested
t analysis of DDR2 protein expression in different cell lines. The protein extracts were
ltswere quantiﬁed using densitometry scanning and expressed as relative ratio compared
GPIN and PCa specimens. Representative data are provided. Original magniﬁcation, ×400.
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samples without bone metastatic lesions (6/12) with relatively lower
level, and in 100% of bone metastatic PCa samples (6/6) with muchFig. 2.DDR2 promotes PCa cells migration and invasion. (A) and (B) Conﬁrmation of the efﬁcien
or GFP, the selected stable clone was analyzed for mRNA and protein expression level using RT
healing assay. (D) DDR2 over-expression increases cell invasion in the Matrigel transwell cham
properties were expressed in terms of number of cells per mm2. (E) and (F) Conﬁrmation of
shRNA against Ddr2 or scrambled shRNA, and the selected stable clone was analyzed by RT-PC
and invasion. Bar, 200 μm. *p b 0.05 vs control group.higher level. Representative data are shown in Fig. 1C. Collectively,
these results implicated that DDR2may have important roles in prostate
cancer bone metastases.cy of DDR2 over-expression. LNCaP cells were infectedwith lentivirus expressing FcDDR2
-PCR and Western blotting. (C) DDR2 over-expression increases cell migration in wound
bers. Cells from 10 randomly chosen microscopic ﬁelds were counted, and cell invasion
the efﬁciency of DDR2 knock-down. PC-3 cells were infected with lentivirus expressing
R and Western blotting. (G) and (H) DDR2 deﬁciency leads to decrease in cell migration
Fig. 2 (continued).
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To deﬁne the role of DDR2 in prostate cancer bone metastases, we
need to ﬁnd out whether DDR2 has effects on the metastatic properties
of PCa cells. DDR2 was over-expressed in LNCaP cells using lentivirus
which expresses FcDDR2, a constitutively activated form of DDR2. Sev-
eral clones were picked up and tested for the efﬁciency of over-
expression using Western blotting (data not shown). The stable clone
with the highest over-expression efﬁciency was selected, and its DDR2
expression levelwas signiﬁcantly higher compared to that of the controlclone (Fig. 2A and B). The migration and invasion abilities of FcDDR2-
expressing and control cells were tested by monolayer wound healing
assay and matrigel invasion assay. As shown in Fig. 2C, DDR2 over-
expression resulted in an approximate 2-fold increase in the migration
abilities of LNCaP cells. Fig. 2D also showed an elevation of about 1.4-
time in the invasiveness of LNCaP cells after DDR2 expression level
was enhanced.
In order to conﬁrm our ﬁndings, we knocked down the DDR2 ex-
pression in PC-3 cells via speciﬁc shRNA against Ddr2. Scramble shRNA
or shRNA against Ddr2 was cloned into lentivirus packing vector and
1354 Z. Yan et al. / Biochimica et Biophysica Acta 1842 (2014) 1350–1363the recombinant lentivirus were packaged and transducted into PC-3
cells to generate the stable control clones or Ddr2-knock down clones.
As shown in Fig. 2E and F, the RNA and protein levels of DDR2 in theFig. 3.DDR2 in PCa cells accelerates osteoblastogenesis and osteoclastogenesis in the co-culture
DDR2 deﬁcient MDA PCa 2b cells. CM of control or DDR2 knocked down MDA PCa 2b cells wer
staining and subsequent acetic acid elution. (B) The differentiation of MC3T3-E1 cells was inhib
ation was determined by detection of marker genes using real-time PCR. (C) The function of M
mineralization nodules was determined by alizarin red staining. Osteoclast differentiation (D)
marrow cells were treatedwith CM from control and DDR2-silencing PC-3 cells, themRNA level
Osteoclast differentiation (F) and bone resorption (G) are accelerated by treating with CM of Dselected clonewere reduced signiﬁcantly compared to those in controls.
Then their abilities of migration and invasion were analyzed, as shown
in Fig. 2G and H, DDR2 knock-down suppressed the motility of PC-3system. (A) The proliferation ofMC3T3-E1 cells was inhibited due to treatmentwith CMof
e collected to treat MC3T3-E1 cells, and cell proliferation was determined by crystal violet
ited due to treatment with CM of DDR2 deﬁcient MDA PCa 2b cells. Osteoblast differenti-
C3T3-E1 cells was inhibited due to DDR2 deﬁcient in MDA PCa 2b cells. The formation of
and bone resorption (E) are retarded by treating with DDR2 silencing CM. Primary bone
s of differentiationmarker geneswere analyzed and pit-formation assayswere performed.
DR2 over-expressing LNCaP cells. *p b 0.05 vs control group.
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ness occurred in response to DDR2 depletion.
2.3. DDR2 in PCa cells accelerates osteoblastogenesis and osteoclastogenesis
in the co-culture system
After drawing the conclusion that DDR2 promotes prostate cancer
metastases, we tried to elucidate the role of DDR2 in osseousmetastasis,
considering the high expression level of DDR2 in bone-metastatic PCa
cells. We used osteoblastic MDA PCa 2b cells and osteolytic PC-3 cells
to study the involvement of DDR2 in osteoblastic and osteolytic lesions
respectively. The culturemediumof control or DDR2-depletedMDAPCa
2b cells was collected to treat MC3T3-E1 cells. The proliferation of
MC3T3-E1 cells was dramatically inhibited due to treatment with CM
(conditioned medium) of DDR2 deﬁcient MDA PCa 2b cells (Fig. 3A).
The differentiation of MC3T3-E1 cells was retarded, determined by
down-regulated expression of marker genes including ALP, Runx2,
and OCN (Fig. 3B). The formation of mineralization nodules, an impor-
tant indicator of osteoblast function, was also greatly affected after
DDR2 was knocked down in MDA PCa 2b cells (Fig. 3C). These data
suggested that DDR2 in MDA PCa 2b cells promoted the formation of
osteoblastic lesions in vitro. As for the effect of DDR2 on the formation
of osteolytic lesions, we collected the culture medium of control or
DDR2-depleted PC-3 cells to treat primary bone marrow cells. Then os-
teoclast differentiation and bone resorptionwere tested using real-time
PCR and pit formation assays. Expression of differentiation markers,
such as NFATc1, TRAP, and Cathepsin K, were signiﬁcantly decreased,
suggesting the suppressed osteoclast differentiation caused by treat-
ment with the CM of DDR2 silencing PC-3 cells (Fig. 3D). The osteoclast
function and bone resorption were similarly inhibited, determined
by the obvious decrease in β-CTX release (Fig. 3E). Then we used
LNCaP cells, which form mixed lesions (osteoblastic/osteolytic) in vivo,
to perform the co-culture assays for testing the involvement of DDR2
in LNCaP cells-mediated osteoblastogenesis and osteoclastogenesis.Fig. 4.DDR2 depletion alleviates PCa cells-induced osteolytic lesions. (A) Kaplan–Meier curve o
by log-rank test. (B). Representative X-radiographs (6 weeks) of mice from (A). Osteolytic lesiThe enhanced osteoclast differentiation and bone resorption were de-
tected when DDR2 was over-expressed in LNCaP cells (Fig. 3F and G).
Taken together, these data demonstrated that DDR2 played an essential
role in PCa cell-induced osteoblastogenesis and osteoclastogenesis, and
participated in PCa osteoblastic and osteolytic metastases.
2.4. DDR2 promotes prostate cancer osteolytic metastasis in vivo
To validate our in vitro ﬁndings, we employed an intrabone injection
bone metastasis mouse model to test the role of DDR2 in PCa bone me-
tastasis. All control mice that received PBS injections did not develop
osteolytic lesions at all. After 3 weeks, 1 of 12 mice that received PC-3
cell injection developed an osteolytic lesion, and 11 mice developed
osteolytic lesions after 6 weeks, with a frequency of 91.7% (11/12).
However, only 41.7% (5/12) of mice treated with DDR2-depleted PC-3
cells were found to have osteolytic lesions 6 weeks after injection, to a
much slighter degree. The percentages of bone-metastatic-free animals
in the three groups were shown in Fig. 4A. Representative X-ray images
are shown in Fig. 4B.
2.5. DDR2 in PCa cells increase RANKL expression in osteoblasts to stimulate
bone resorption
To ﬁnd out why DDR2 affected osteoclastogenesis in addition to
osteoblastogenesis, we tried to examine whether there was an indirect
effect of osteoclast activation mediated by osteoblasts, since the cancer
bone metastatic site is a microenvironment comprising cancer cells, os-
teoblasts, osteoclasts, osteocytes, and interaction between them, and
the differentiation and activation of osteoclasts require co-stimulating
factors provided by osteoblasts in PCa osteolysis lesions. We examined
whether the secretion of RANKL or OPG in osteoblasts was affected by
the change of DDR2 expression level in PCa cells. The culture medium
of the control and DDR2 modiﬁed PCa cells was collected for treating
MC3T3-E1 cells, and the expression of RANKL and OPG in MC3T3-E1f bone metastasis development of control and DDR2-silencing PC-3 cells. N= 12. *p b 0.05
on is marked by red arrow.
Fig. 5.DDR2 in PCa cells increases RANKL expression in osteoblasts to stimulate bone resorption. (A) and (B) The effect of DDR2 depletion on themRNA level of RANKL andOPG.MC3T3-E1
cells were treated with CM from control and DDR2 over-expressing LNCaP cells. 5 d later the mRNA levels of the RANKL and OPG were analyzed. (C) The effect of DDR2 depletion on the
protein level of RANKL andOPG. (D) Bone resorptionwas greatly suppressed in the presence of osteoblast. RAW264.7 cellswere co-culturedwith orwithoutMC3T3-E1 cells in 10%DMEM
containing 50% (v/v) CM, after 3 d of induction the culture supernatant was collected for assaying β-CTX. *p b 0.05 vs control of conditioned medium group; N.S. means non-signiﬁcant.
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induced by the CM of DDR2 knock-down PC-3 cells was dramatically
decreased, whereas the mRNA level of OPG has no obvious change.
The protein levels of RANKL and OPG were consistent with the mRNA
levels (Fig. 5C). In the presence of osteoblasts, the bone resorption
was signiﬁcantly suppressed when treated with CM of DDR2 deﬁcient
PC-3 cells (Fig. 5D). Similarly, the expression of RANKL was elevated
(Fig. S1A)while that of OPGwas reduced (Fig. S1B), due to the treatment
of CM of DDR2 over-expressing LNCaP cells. The bone resorption was
also dramatically stimulated in the presence of osteoblast (Fig. S1C).
Collectively, these results implicated that DDR2 in PCa cells modulated
RANKL expression of osteoblasts in a paracrine manner, and the DDR2-
induced osteoclast activation and bone resorption were osteoblast-
dependent.
2.6. DDR2 regulates PTHrP in PCa cells
To reveal the mechanism whereby DDR2 promoted PCa bone metas-
tases, we tried to ﬁnd out the DDR2-regulated genes involved in this reg-
ulation. The expression level of bonemetastatic factors such as PTHrP, IL8,
or IL11 were examined, since these genes were reported to up-regulate
RANKL level of osteoblasts [11–15]. After DDR2 was modiﬁed, only
expression of PTHrP was changed. As shown in Fig. 6A and B, DDR2
over-expression led to signiﬁcantly enhancement of PTHrP expression,
whereasDDR2knockdownby speciﬁc siRNA resulted in dramatic impair-
ment of PTHrP expression. The secretion of PTHrP in PC-3 cells waselevated to about 4-time due to DDR2 over-expression, andwas remark-
ably attenuated due to DDR2 deﬁciency (Fig. 6C). Next, we detected the
activity of PTHrP promoter using a pGL3-luc plasmid containing the se-
quence between−1450 and 300 nt around the transcription start site.
As shown in Fig. 6D, the promoter activity of the DDR2 over-expressing
cells was greatly increased, to a similar extent of Runx2 induction,
while that of DDR2 deﬁcient cells was remarkably decreased.
Runx2 is one of the known transcription factors regulating PTHrP
expression. In our previous study, we proved that DDR2 modiﬁed
the phosphorylation and transcriptional activity of Runx2 in osteoblasts
and chondrocytes, so we wondered whether DDR2 could regulate
PTHrP expression via modulation of Runx2 activation. To clarify the
facts, we introduced a constitutively activated Runx2 vector, which
contains Ser to Glu mutations and mimics the phosphorylation and
transcriptional activation of Runx2 [43], into the stable DDR2-silenced
PC-3 cells, to perform a rescue experiment. In Fig. 6E, we observed
that introduction of Runx2 S301/319E mutant (with enhanced Runx2
phosphorylation) in shDDR2-transduced PC-3 cells rescued the de-
creased expression level of PTHrP caused by DDR2 deﬁciency, whereas
an empty vector failed to show the rescue ability. Conversely, S301/
319A Runx2mutant, the inactivating Ser to Ala mutationswith reduced
phosphorylation and transcriptional ability of Runx2, led to a decrease
in PTHrP expression (Fig. 6F). Taken together, these results demonstrat-
ed that DDR2 regulated the expression and secretion of PTHrP in PCa
cells via affecting the phosphorylation of Runx2, and there was a
DDR2-Runx2-PTHrP axis.
Fig. 6.DDR2 regulates PTHrP in PCa cells. (A) DDR2 regulates themRNA level of PTHrP in PC-3 cells. Cellswere transfectedwith FcDDR2 plasmid or siDDR2, 24 h latermRNA level of PTHrP
were determined by RT-PCR. (B) DDR2 modulates the protein level of PTHrP in whole lysate of PC-3 cells. (C) DDR2 modulates the secretion of PTHrP in PC-3 cells. 48 h after the trans-
fection, the culture mediumwas harvested for analyzing the secreted PTHrP level. (D) DDR2 regulates the promoter activity of PTHrP. 24 h after the transfection, pGL3-luc and phRL null
vector were transfected into the cells, 48 h later the luciferase activities were assayed. (E) Constitutively activated mutation of Runx2 rescued the decreased PTHrP expression caused by
the loss of DDR2. DDR2 knock-down PC-3 cells were transfected with empty vector or Runx2 S301/319E, 24 h later the cells were harvested and the protein level of PTHrP was tested by
Western blotting. (F) Runx2 S301/319A abolished the FcDDR2 induction of PTHrP up-regulation. DDR2 over-expressing LNCaP cells were transfected with empty vector or Runx2 S301/
319A, 24 h later the cells were harvested and the protein level of PTHrP was tested by Western blotting. *p b 0.05 vs control group.
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metastasis inducer
We have proved in the above section that DDR2 promotes prostate
cancer bone metastasis by inducing PTHrP secretion viamodulation ofRunx2 phosphorylation. However, there are still some questions that
need to be answered. How does the up-regulation of DDR2 in expres-
sion or activity occur? Which molecule triggers DDR2 in the process of
bone metastasis? Given that TGF-β is one of the most important medi-
ators in the prostate cancer microenvironment and the vicious cycle
1358 Z. Yan et al. / Biochimica et Biophysica Acta 1842 (2014) 1350–1363between cancer cells and bone cells, we investigated the responsiveness
of DDR2 to TGF-β and tried to ﬁnd out whether TGF-β facilitates the
bone metastasis promotion effect of DDR2. As shown in Fig. 7A, after
treatment of TGF-β, the protein level of DDR2 in PC-3 cells was in-
creased signiﬁcantly, followed by an enhancement of phosphorylation
level of Runx2 and expression level of PTHrP.
Then we detected the transcriptional activity of Runx2 to see if it is
affected by TGF-β treatment. The speciﬁcity of the probe for Runx2 is
veriﬁed by cold probe competition assay and antibody-binding super-
shift assay (Fig. 7B, lanes 1–6). When a labeled wild-type probe was in-
cubated with the nuclear extracts from LNCaP cells, a band shift was de-
tected, indicating that the nuclear proteins effectively bound and formed
a complex with the probe (Fig. 7B, lanes 1 and 2). The addition of 300-
fold excess of unlabeled wild-type but not mutant probe abolished the
formation of the protein–DNA complex (Fig. 7B, lanes 3 and 4). Further-
more, a super-shift band was observed above the previous band shiftFig. 7. DDR2 is responsive to TGF-β stimulation. (A) TGF-β treatment leads to up-regulation of
starved before being treated with or without 200 ng/mL TGF-β1 for 48 h. The expression l
of Runx2 is stimulated by TGF-β. LNCaP cells were treated as described in (A), and the nucle
(C) TGF-β induces the production of PTHrP via DDR2 in PC-3 cells. PC-3 cells were treated with
cation by ELISA. (D) DDR2 mediated the up-regulation of RANKL expression induced by TGF-β
medium of MC3T3-E1 and the mRNA level of RANKL in MC3T3-E1 was detected by real-time
this regulation. Primary bonemarrow cells were treatedwith CM fromDDR2 over-expressing a
in the TGF-β-free group; p b 0.05 vs control in the TGF-β-treated group.when the nuclear extracts were pre-incubated with an antibody against
Runx2 but not unimmunized goat IgG (Fig. 7B, lanes 5 and 6). Hence the
probe in this system is speciﬁc for Runx2 binding. As shown in Fig. 7B
(lanes 7 and 8), the DNA binding ability of Runx2 in LNCaP cells was
signiﬁcantly elevated after being treated by TGF-β.
Finally, we detected the amount of PTHrP secreted to the culture
medium using ELISA. As shown in Fig. 7C, the production of PTHrP in
PC-3 cells was approximately 4-time higher when treated with TGF-β,
whereas the up-regulation was not so obvious in DDR2-silencing PC-3
cells. We co-cultured the PC-3 cells with MC3T3-E1 cells and detected
the mRNA level of RANKL in MC3T3-E1 cells. As shown in Fig. 7D, The
mRNA of RANKL was dramatically induced after adding TGF-β to the
condition medium, whereas DDR2-silencing PC-3 cells were not as
responsive as the control cells. The function of osteoclasts and osteoclas-
togenesis was obviously accelerated by TGF-β treatment and at least
partly, DDR2 contributes to this effect (Fig. 7E).DDR2 expression, Runx2 phosphorylation, and PTHrP production. PC-3 cells were serum
evels of indicated protein were determined by Western blotting. (B) The transactivity
ar protein was extracted and the DNA binding abilities of Runx2 were assayed by EMSA.
200 ng/mL of TGF-β1 for 48 h and the culture mediumwas collected for PTHrP quantiﬁ-
. The CM from DDR2-silencing and control cells were harvested and added to the culture
PCR. (E) The activities of osteoclasts were enhanced by TGF-β and DDR2 was involved in
nd control cells as described above, pit formation assay was performed. *p b 0.05 vs control
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Given that DDR2 could be bound and activated by type I collagen,
which makes up more than 90% of the total protein within the bone,
we detected the binding abilities of PCa cells to collagen I owing to
DDR2. As shown in Fig. 8A, bone metastatic PC-3 and VCaP cells,
which express high levels of DDR2 (Fig. 1), had stronger abilities to
bind collagen I, with an about 4-time increase compared to non-bone
metastatic PCa cells, whereas there was no difference in their abilities
of binding to ﬁbronectin. Then the effect of DDR2 on speciﬁc binding
to collagen I was tested. As indicated in Fig. 8B, over-expression of
DDR2 in LNCaP cells led to a signiﬁcant elevation in speciﬁc binding
of collagen I, whereas depletion of DDR2 in PC-3 cells resulted in aFig. 8. DDR2 facilitates the adhesion of PCa cells to collagen I. (A) Collagen I binding abil-
ities of PCa cell lines. Collagen I, ﬁbronectin or BSA was coated on cell culture dishes, and
PCa cells were seeded on the pre-coated dishes for performing the cell adhesion assay. The
percentage of speciﬁc binding to either type I collagen or ﬁbronectin was calculated by
subtracting the mean nonspeciﬁc binding to BSA. *p b 0.05 vs collagen I-treated DU145
or LNCaP group. (B) Effect of DDR2 on collagen I binding abilities. DDR2 over-expression
in LNCaP led to increase in collagen I binding, whereas DDR2 knock down in PC-3 cells
resulted in decrease. *p b 0.05 vs control LNCaP group; p b 0.05 vs control PC-3 group.
(C) Pre-incubation of recombinant DDR2 protein impaired the binding of PC-3 cells to
collagen I. 10 μg/mL recombinant DDR2 protein was pre-incubated for 45 min at 37 °C,
and speciﬁc binding was assayed. *p b 0.05 vs DDR2-free collagen I-treated PC-3 group.dramatic decline. To further conﬁrm the speciﬁc role of DDR2, recombi-
nant DDR2 protein was used to block the function of DDR2, and the
binding abilities of LNCaP and PC-3 cells to type I collagen were ana-
lyzed. As shown in Fig. 8C, when pre-incubation of recombinant DDR2
protein was carried out, the binding of PC-3 cells to type I collagen
dropped dramatically to approximately one-half. However, no obvious
change in ﬁbronectin-binding was observed after the recombinant
DDR2 protein pre-incubation.
Taken together, the role of DDR2 in prostate cancer bone metastasis
could be displayed in the schematic diagram (Fig. 9). TGF-β in tumor
microenvironment stimulates DDR2 expression. DDR2 facilitates the
speciﬁc binding of PCa cells to collagen I, which is the main component
of bone. In the bone metastasis site, up-regulation of DDR2 expression
and activation leads to phosphorylation and activation of Runx2, as
well as the following release of PTHrP. Osteoblastogenesis was pro-
voked by PTHrP and meanwhile osteoblasts expressed more RANKL
to accelerate osteoclast differentiation and bone resorption. Thus
DDR2 contributed to both osteoblastic and osteoclastic lesions in bone
metastasis.
3. Discussion
Prostate cancer dissemination and skeletal metastases represent
major therapeutic challenges. Once the skeletal metastasis occurs, the
incurable patient could just be symptomatically treated to alleviate
the pain. Therefore it is of great necessity to disclose the molecular
mechanisms underlying PCa metastasis and its propensity for bone, as
well as uncovering the potential targets for future research. We found
that the expression level of DDR2 was signiﬁcantly higher in bone met-
astatic PCa cells and tissues, which prompted us to investigate the role
of DDR2 in PCa dissemination and bone metastases. DDR2 has been
implicated in playing essential roles in other cancer types but PCa. Our
previous study suggested the function of DDR2 in the regulation of the
transactivity and phosphorylation of Runx2, a key regulator of PCa
bone metastasis. Based on these ﬁndings, we hypothesized that DDR2
promotes PCa metastasis and bone-homing via Runx2 regulation.
In the present study, we initially observed that the expression level
of DDR2 was notably elevated in the bone metastatic PCa cells and tis-
sues, compared with normal and non-bone-metastatic controls. DDR2
positively regulated the migration and invasion abilities of PCa cells.
DDR2 in PCa cells stimulated osteoblastogenesis and osteoclastogenesisFig. 9. A schematic model depicting molecular mechanisms underlying DDR2-mediated
prostate cancer bone metastasis. TGF-β in tumor microenvironment stimulates the
expression of DDR2, which is responsible for the Runx2 activation and subsequently
PTHrP secretion. In bone metastasis site, PTHrP promotes osteoblast proliferation, differ-
entiation and function, at the same time DDR2 stimulates RANKL expression in osteo-
blasts, leading to the activation of osteoclasts and enhanced osteoclastogenesis.
Furthermore, DDR2 facilitates the speciﬁc binding of PCa cells to collagen I, which is the
main component of bone.
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underlyingmechanismwas that DDR2 in PCa cells regulated the expres-
sion, secretion, and promoter activity of PTHrP via regulating the
transactivity and phosphorylation of Ruxn2, to affect the RANKL expres-
sion of osteoblasts, which in turn stimulated osteoclast activation and
bone resorption. Moreover, DDR2 was responsive to TGF-β stimulation
and participated in the TGF-β-induced bone resorption. DDR2 also me-
diated the adhesion of PCa cells to type I collagen, the main component
of bone.
DDR2 has been implicated in the progression of several types of can-
cer. DDR2 participates in the liver metastasis of melanoma, contributes
to colorectal dissemination by increasingmyoﬁbroblasts, neoangiogenic
vessels and proliferating cancer cells. DDR2 is closely associated with
nasopharyngeal carcinoma (NPC) and aneuploid papillary thyroid carci-
nomas, and is involved in EMT of several types of cancer cells including
breast and lung cancer cells using distinctmechanisms. Activatedmuta-
tion of DDR2 was also found in lung squamous-cell carcinoma. How-
ever, there is another report regarding the negative regulatory role of
DDR2 in tumor progression (DDR2deﬁciencypredisposes hepatic tissue
to colon carcinoma) [44], suggesting that the role of DDR2 in tumors is
complicated and cellular context dependent. Until now there is no liter-
ature reporting the roles of DDR2 in PCa and PCa bone colonization. Our
original study implicates DDR2 in PCa bone metastasis for the ﬁrst time
and is of great signiﬁcance for the future treatment of prostate cancer.
Moreover, the target genes downstream of DDR2 are largely unknown,
and the detailed signaling pathways mediating DDR2 regulation of
target gene transcription are poorly understood. In the present study,
we demonstrated that PTHrP is regulated by DDR2 in PCa cells. This
ﬁnding expands the DDR2-Runx2 axis to TGFβ-DDR2-Runx2-PTHrP
pathway.
Prostate cancer bone metastases result in mixed, heterogeneous
osteoblastic and osteolytic lesions. Osteoblastic lesions are character-
ized by excess deposition of new bone, whereas osteolytic lesions are
characterized by the destruction of bone. These two types of PCa bone
metastases all cause disturbance of bonemicroenvironment homeosta-
sis. PCa cells secrete factors that stimulate the proliferation and dif-
ferentiation of osteoprogenitor cells, or induce osteoclast precursors
differentiate into mature osteoclasts in the tumor environment. Al-
though clinically osteoblastic lesions account as a major component,
there are still existing osteolytic lesions which are due to the activation
of osteoclasts. It is unknown which kind of bone metastatic lesions, os-
teoblastic or osteolytic, occur initially. In our study, we demonstrated
that the formation of osteolytic lesions required osteoblasts, suggesting
the initiating role of osteoblastic lesions in PCa bone metastases. DDR2
acted as a stimulator for PCa bone metastases via regulating PTHrP,
which has been implicated to function in an autocrine, paracrine
or intracrine manner. Here we only discussed the paracrine manner
of PTHrP to inﬂuence the bone microenvironment. Other aspects of
PTHrP function, such as stimulating cell proliferation, adhesion and sur-
vival by directly acting on tumor cells, were not investigated in this
study. Our results showed that PCa cell-derived PTHrP was responsible
for the stimulated osteoblast proliferation and activation, as well as the
promoted osteoclast differentiation and bone resorption, being consis-
tent with previous reports [45].
In the process of PCa cells metastasizing to the bone, PCa cells pro-
duce MMPs and other enzymes to degrade the basement membrane
and invade the bloodstream from the primary site. Based on our previ-
ous studies, DDR2 activation led to the secretion and activation of
MMP2, 13 (Fig. S2). So we speculated that in the early stage of PCa
bone metastasis, DDR2-MMPs axis accounts for a larger contribution.
Then the circulating PCa cells with high DDR2 expression levels are
speciﬁcally attracted by type I collagen, which is the most abundant
extracellular matrix protein in bone. In the bone metastatic site, PTHrP
is stimulated by DDR2 activation and acts on osteoblasts to stimulate
osteoblast differentiation and bone formation, or accelerate the differ-
entiation of osteoclasts and bone resorption. TGF-β is then releasedfrom the bone reservoir and regulates the expression of DDR2. Thus,
DDR2 acts an important mediator in the vicious cycle of tumor cell pro-
liferation and bone destruction. Collectively, DDR2 functions at different
levels (invasion, homing, pro-osteoblastic, pro-osteoclastic) to promote
PCa bone metastasis.
However, there are still some issues that remain poorly understood.
For instance, how TGF-β modulates DDR2 expression and whether
Smads participate in the regulation. How does DDR2 regulate the
expression of PTHrP via Runx2? Is there any other kinase downstream
of DDR2 participating in PTHrP regulation, such as p38? These questions
would be answered in our future studies.
4. Materials and methods
4.1. Antibodies and reagents
The antibodies used in this study were as follows: goat anti-DDR2
(R&D Systems, MN, USA), rabbit anti-Runx2 S533 (Epitomics, CA,
USA), goat anti-PTHrP (Santa Cruz, CA, USA). Recombinant human
TGF-β1, recombinant murine M-CSF and sRANKL were purchased
from Peprotech (NJ, USA). Ascorbic acid (AA) and β-glycerophosphate
(β-GP) were purchased from Sigma (Shanghai, China), Type I collagen
and ﬁbronectin were purchased from BD Biosciences (MA, USA).
Recombinant human DDR2 protein was purchased from Abnova (CA,
USA). The Runx2 S301/319E and Runx2 S301/319A plasmid were
described previously [33]. The−1450 to 300 of PTHrP gene (PTHLH)
promoter were ampliﬁed by PCR and inserted into pGL3-luc vector
(Promega, WI, USA) using Kpn I and Xho I.
4.2. Cell culture
Normal prostate epithelial RWPE-1 was cultured in K-SFM
(Invitrogen, CA, USA) supplementedwith 50 μg/mL bovine pituitary ex-
tract (BPE), 5 ng/mL EGF and 10% fetal bovine serum (FBS). PCa cell
lines LNCaP, DU145, MDA PCa 2b, PC-3 and VCaP were cultured in
Dulbecco's modiﬁed essential medium (DMEM) supplemented with
10% FBS. Murine RAW264.7 cells and primary bone marrow cells were
cultured in DMEM supplemented with 10% FBS. Murine pre-osteoblast
cell MC3T3-E1 (subclone 14) were cultured in α-minimal essential
medium (α-MEM, Invitrogen, CA, USA) with 10% FBS. All cells were
maintained in a humidiﬁed atmosphere with 5% CO2 at 37 °C.
4.3. Immunohistochemistry
This study was approved by the Ethics Committee of The First Afﬁl-
iated Hospital of Xi'an Jiaotong University College. Nineteen BPH and
HGPIN samples and 18 PCa samples (6 cases with bone metastatic
lesions) were ﬁxed in 10% neutralized formalin and embedded in
parafﬁn blocks. Sections (4 μm) were prepared for the evaluation of
DDR2 expression. For immunohistochemical analysis, the endogenous
peroxidase activitywas blocked using 3%H2O2 for 1 h, followed by incu-
bation with 5% Serum-Free Protein Block and then primary antibody
anti-DDR2 (1:100) at 4 °C overnight. Immunodetection was performed
in a 3-step protocol, using streptavidin-horseradish peroxidase com-
plex, with visualization by 3,3-diaminobenzidine.
4.4. Co-culture assay
Cell conditioned medium (CM) was collected from DDR2 modiﬁed
PCa cells. The medium was harvested, sterile ﬁltered and stored at
−20 °C until needed. In co-culture assay, MC3T3-E1 cells were seeded
at the density of 5 × 104/cm2, and cultured in 10%α-MEM supplement-
edwith 50% (v/v) CM in the presence of osteogenic inducers: 50 mg/mL
AA and 5 mM β-GP. Alternatively primary bone marrow cells were
seeded at thedensity of 4×103/cm2, and cultured in 10%DMEMsupple-
mented with 50% (v/v) CM, in addition with 50 ng/mL M-CSF and
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ed time point the differentiation was determined by real-time PCR
detection of mRNA levels of marker genes.
4.5. Lentivirus packaging and infection
The lentivirus system for short hairpin RNA (shRNA) expression in-
cluded three plasmids (pLKO.1, psPAX2, and pMD2.G) andwasobtained
from Addgene (Cambridge, MA, USA). Sense and antisense shDNA
oligos were annealed and ligated into the pLKO.1 vector, generating
plasmids that expressed shRNAagainst DDR2or a scramble RNA respec-
tively. FcDDR2 was inserted into the lentivirus shuttle vector designed
for cDNA expression. Then 3 × 105 HEK-293 T cells at 70% conﬂuence
were transfected with 1 μg of shuttle vector, 750 ng of psPAX2, and
250 ng of pMD2.G using Lipofectamine2000 (Invitrogen, CA, USA).
Twelve hours after transfection, the medium was changed. Cells were
cultured for an additional 36 h before the culture mediumwas harvest-
ed. Once target cells reached 50% conﬂuence, they were incubated with
virus-containing medium for 48 h and further grown in medium con-
taining 6 μg/mL of puromycin (Invitrogen, CA, USA). After 3 weeks of
selection, single colonies were picked up and tested for their expression
level of DDR2. The most efﬁcient modiﬁed clone was used for further
studies.
4.6. Quantitative real-time PCR analysis
Total RNAwas extracted using Trizol (Invitrogen, CA, USA). Comple-
mentary DNA (cDNA) was synthesized from 2 μg of total RNA using
the Super-Script II First-Strand Synthesis System (Invitrogen, CA,
USA). The mRNA levels were determined either by semiquantitative
reverse-transcriptase PCR (RT-PCR) or by quantitative real-time PCR.
The glyceraldehyde-3-phosphate dehydrogenase (Gapdh) gene was
used as an endogenous control. The sequences of primers for various
genes are shown in Table 1. Details of the reaction system and ampliﬁ-
cation procedure were described previously [33].
4.7. Western blotting
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer
supplementedwith protease inhibitors (Roche, NJ, USA). Protein lysates
were subjected to 10% SDS-PAGE, transferred to nitrocellulose mem-
brane (Bio-Rad, CA, USA), and incubated with the indicated antibody.Table 1























Reverse 5′-CAGGCGCCCAATACGACCAAATC-3′Bands were developed with enhanced chemiluminescence (ECL)
system (Amersham Bioscience, UK). The blots were reprobed with
β-actin antibody for the loading control.
4.7.1. Cell proliferation assay
MC3T3-E1 cells were plated in 24-well plates (5 × 103/well) in qua-
druplicate and cultured in the culture medium supplemented with 50%
CMof control or DDR2-depletedMDA PCa 2b cells. At the indicated time
point, cells were ﬁxed for staining with 0.5% (w/v) crystal violet.
Destaining was carried out with 35% (v/v) acetic acid and the absor-
bance was read at 570 nm. The optical density was used to represent
the relative cell number.
4.7.2. Alizarin red staining
Cells were ﬁxed with 95% ethanol, and then further treated with
40 mM alizarin red stain (AR-S) solution (pH 4.2) for 30 min to label
the calcium deposits. The stained cultures were photographed, and
the AR-S was extracted with 10% (w/v) cetylpyridinium chloride in
10 mM sodium phosphate (pH 7.0). The AR-S concentration was deter-
mined by measuring the absorbance at 540 nm using an AR-S standard
curve.
4.8. Luciferase report assay
Cells were transiently transfectedwith 1 μg pGL3-luc reporter vector
plus 0.05 μg pRL-null Renilla luciferase vector (Promega,WI, USA) using
Roche Transfection reagents, 48 h later cell lysates were harvested and
the luciferase activity in the cell lysates was assayed using the Dual
Luciferase Reporter Kit (Promega, WI, USA). Transfections were per-
formed in triplicate and normalized to Renilla luciferase activity.
4.9. Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was performed accord-
ing to the kit procedure (Pierce, IL, USA). Nuclear extracts were pre-
pared using the NE-PER nuclear and cytoplasmic extraction reagents
(Pierce, IL, USA). The sequences of probes are shown in Table 2. Nuclear
proteins (3 μg) were incubated with 20 fmol of biotin-labeled wt-probe
or mt-probe, and the DNA–protein complex was separated on a 6%
nondenaturing polyacrylamide gel in 0.5× TBE with 2.5% glycerol and
transferred to positively charged nylon membranes. The membranes
were blocked with blocking buffer and incubated with HRP-conjugated
streptavidin. The blots were developed with chemiluminescence sub-
strate solution (Pierce, IL, USA) and exposed to X-ray ﬁlm. For competi-
tion assays, 300-fold excess of unlabeled probes were added to the
reaction mixture for 30 min at room temperature before the addition
of the labeled probe.
4.10. Wound healing assay
Cells were cultured in 35mmdisheswithDMEM containing 10% FBS
until they reached subconﬂuence, then the monolayer was scratched
with a 200 μL pipette tip. Cells were washed with PBS twice and cul-
tured in FBS-free medium for additional 48 h. Cell migration into theTable 2






Note: The underlined characters indicate the mutation site. A 5′-biotin modiﬁcation was
included in all probes except for the competitor oligonucleotides, which did not contain
any modiﬁcation. wt: wild type; mt: mutant type.
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the indicated time point, and analyzed using Leica LAS EZ software.
The distance of cell migration was calculated as the migration distance
(mm) by subtracting the distance between the lesion edges at 48 h
from the distance measured at 0 h.
4.11. Cell invasion assay
Cell invasion experiments were performed using Bio-Coat cell migra-
tion chambers (BD Biosciences, MA, USA), which consist of a 24-well
companion plate with cell culture inserts containing a ﬁlter with 8 μm-
diameter pores. Filters were coated with basement membrane Matrigel
(40 μg/ﬁlter). Cells resuspended in DMEM/BSA medium (3 × 105 cells/
500 μL) were added to the insert (upper chamber), and DMEM contain-
ing 20% FBS was placed in the lower chamber (800 μL/well). After incu-
bation at 37 °C for 48 h, the upper surface of the membrane was wiped
with a cotton-tipped applicator to remove non invading cells, the invad-
ing cells on the under surfacewere ﬁxedwith 5% glutaraldehyde ﬁxative
and stained with Giemsa. Cells from 10 randomly chosen microscopic
ﬁelds were counted and cell invasion was expressed in terms of number
of cells per mm2.
4.12. Cell adhesion assay
Cells were seeded on 1 μg/cm2 Collagen I, ﬁbronectin or BSA-coated
dishes, which were pre-treated by the removal of excess protein and
blocking with medium containing 1% BSA for 1 h at 37 °C. After a 2 h
incubation at 37 °C, nonadherent cells were removed, and adherent
cells were ﬁxed and stained with 0.5% (w/v) crystal violet. Destaining
was carried out with 35% (v/v) acetic acid and the absorbance was
read at 570 nm. The percentage of speciﬁc binding to either type I colla-
gen or ﬁbronectin was calculated by subtracting the mean nonspeciﬁc
binding to BSA. To characterize the speciﬁc role of DDR2, the adhesion
assay was followed by a 45-minute, 37 °C preincubation of the 10 μg/mL
recombinant DDR2 protein.
4.13. Pit formation assay and β-CTX quantiﬁcation
Mouse primary bone marrow cells or RAW264.7 cells were seeded
on the BioCoat™ Osteologic™ dishes (BD Biosciences, MA, USA) at
the density of 4 × 103/cm2 and cultured in 10% DMEM containing
50% (v/v) CM, 50 ng/mL M-CSF, and 100 ng/mL RANKL. Alternatively,
RAW264.7 cells and MC3T3-E1 cells were co-cultured at the ratio of
1:1 in 10% DMEM containing 50% (v/v) CM. The medium was replaced
every other day, and after 3 d of induction the culture supernatant
were collected and assayed for the amount of β-CTX, which was used
to indicate the extent of bone resorption. The procedure of β-CTX
quantiﬁcation was as described in the manufacturer's instructions
(Elabscience Biotechnology, China).
4.14. Animal experiment
An intrabone injection model of bone metastasis was used to con-
ﬁrm the in vitro results. All procedures were performed in compliance
with the Xi'an Jiaotong University of Animal Care and Use Committee.
Six-week-old male severe combined immunodeﬁciency disease (SCID)
mice were housed in a facility with constant humidity and temperature
and a 12-h light–dark cycle. After the animals were anesthetized with
i.m. injections of 100 mg ketamine/10 mg xylazine/kg body weight,
a 26-gauge needle was inserted into the proximal end of the tibia
and 100 μL of cell preparation containing 1 × 106 control or DDR2-
depleted PC-3 cells was injected. The same volume of PBS was injected
as negative control. Animals were monitored daily for signs of tumor
burden. After 3 weeks, radiographs of the bones were obtained (35 kV,
15 s, 20.7 mA/s, small focal setting).4.15. Statistical analysis
Each experiment was repeated at least three times, unless indicated
otherwise. The results obtained from a typical experiment were
expressed as the mean ± standard deviation. Statistical analysis was
performed using GraphPad Prism 4. Signiﬁcant differences were deter-
mined using students t test, p value less than 0.05 was considered
signiﬁcant.
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